Cannasouth adds manufacturing capability with strategic acquisition

The Board of Cannasouth Limited (NZX: CBD) announced today it had entered into an agreement to acquire a 60 per cent shareholding in Hawkes Bay-based Midwest Pharmaceutics NZ Limited for a purchase price of $1.32 million.

• Cannasouth expands with acquisition of an initial 60% stake
in Midwest Pharmaceutics NZ Limited (Midwest).
• The acquisition will accelerate Cannasouth’s development of
its medicinal cannabis business in New Zealand and will
provide immediate revenues from the date of acquisition.
• The acquisition will add significantly to the suite of
licences that can be utilised by the Cannasouth group.
• The acquisition complements the recent joint venture
entered into with Mr Aaron Craig to form Cannasouth
Cultivation Limited for the development and cultivation of
medicinal cannabis in the Waikato region.
• The acquisition significantly progresses the Company’s key
vertical integration strategy “from seed to sale”.

Please see the Market Announcement for full details.

CBD takes strategic stake in Midwest Pharmaceutics

Back to top